Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

As a result, a market for cheaper, off-brand versions of their active ingredients — semaglutide and tirzepatide — has ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.